Merck KGaA (MRK) Given a €108.00 Price Target by Sanford C. Bernstein Analysts

Merck KGaA (FRA:MRK) has been given a €108.00 ($125.58) price target by equities research analysts at Sanford C. Bernstein in a research report issued on Tuesday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the healthcare company’s stock. Sanford C. Bernstein’s target price indicates a potential upside of 17.21% from the stock’s current price.

Other equities analysts have also recently issued reports about the company. Kepler Capital Markets set a €108.00 ($125.58) target price on Merck KGaA and gave the company a “buy” rating in a research note on Thursday, January 24th. UBS Group set a €115.00 ($133.72) price target on Merck KGaA and gave the company a “buy” rating in a research report on Thursday, March 7th. Credit Suisse Group set a €110.00 ($127.91) price target on Merck KGaA and gave the company a “buy” rating in a research report on Friday, March 8th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Merck KGaA in a research report on Tuesday, January 15th. Finally, Morgan Stanley set a €90.00 ($104.65) price target on Merck KGaA and gave the company a “neutral” rating in a research report on Monday, February 11th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have given a buy rating to the stock. Merck KGaA currently has an average rating of “Hold” and a consensus target price of €101.10 ($117.56).

Shares of MRK traded down €3.54 ($4.12) during mid-day trading on Tuesday, hitting €92.14 ($107.14). 885,044 shares of the company’s stock traded hands. Merck KGaA has a 1 year low of €76.60 ($89.07) and a 1 year high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: Trading based on a resistance level

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.